# Average correctness_score: 1.68,,,,,,,,
# Average completeness_score: 1.58,,,,,,,,
# Average conciseness_score: 1.68,,,,,,,,
# Average faithfulness_score: 2.65,,,,,,,,
question,correctness_score,correctness_explanation,completeness_score,completeness_explanation,conciseness_score,conciseness_explanation,faithfulness_score,faithfulness_explanation,input_tokens,output_tokens,response_time_seconds,error,raw_response
How many studies are in cBioPortal?,2.0,"The LLM correctly directs users to the datasets page (https://www.cbioportal.org/datasets) which matches the expected answer. However, it provides a vague answer ('hundreds of cancer studies') rather than attempting to provide a specific count, and lists various study types that appear to be general knowledge rather than verified from the source.",2.0,"The output partially addresses the question by directing users to where they can find the study count, but it doesn't actually answer 'how many' studies exist. It acknowledges it cannot provide a direct count and redirects to the appropriate resource, which is helpful but incomplete as an answer to the specific numerical question asked.",1.0,"The output is excessively verbose. It includes unnecessary information about specific study types (TCGA, ICGC, TARGET), offers to help with additional searches, and provides examples of follow-up questions. A simple answer directing to the datasets page would have been sufficient for this straightforward question.",2.0,"While the LLM correctly references the datasets page from the expected answer, it includes extensive details about study types (TCGA, ICGC, TARGET, institutional studies, cell line data) that don't appear to be verified from the provided context/source. These details seem to come from general knowledge about cBioPortal rather than the specific source material provided.",21145,288,7.617682473966852,,
How many glioblastoma studies are in cBioPortal?,3.0,"The LLM Output correctly identifies 7 glioblastoma studies in cBioPortal, which matches the data returned from the database query showing 'totalCount': 7 and listing all 7 study IDs.",3.0,"The answer fully addresses the question by providing the total count (7 studies) and goes beyond by listing all studies with their names and sample counts, giving comprehensive information.",2.0,"While the core answer (7 studies) is provided clearly, the output includes extensive additional details about each study (sample counts, categorization into TCGA vs other studies, and a recommendation about the PanCancer Atlas) that, while useful, make it somewhat verbose for a simple count question.",3.0,"All information in the output is directly traceable to the database query results shown in the Context/Source. The study names, sample counts, and total count of 7 studies all match the returned data exactly.",45761,407,8.976075001060963,,
How many patients and samples are in the MSK-CHORD Study?,2.0,"The LLM correctly identifies the sample count as 25,040 samples. However, it does not provide the patient count, only stating that it will be shown on the study page. The URL provided is also incorrect - it points to a deploy-preview URL instead of the expected production URL (www.cbioportal.org).",2.0,"The answer is only partially complete. It provides the sample count (25,040) but fails to provide the patient count, which was explicitly asked for in the question. The LLM acknowledges that patient count exists but doesn't retrieve or display it.",2.0,"The output is somewhat verbose. While the tool calls and their results are informative, the final answer includes unnecessary details about what will be shown on the study page, additional study characteristics, and a description of MSK-CHORD that wasn't requested. A more concise answer would simply state the patient and sample counts.",3.0,"The LLM Output relies entirely on the data retrieved from the cBioPortal database through the tool calls. The sample count of 25,040 comes directly from the API response, and the study metadata is accurately represented. No external information or hallucinations are present.",65014,398,11.330137582030147,,
How many primary samples are in the MSK-CHORD Study?,1.0,"The LLM Output does not provide the actual number of primary samples. It only states that the total study contains 25,040 samples across all types and directs the user to a filtered view to find the answer themselves. The expected answer shows a specific URL that would contain this information, but the LLM failed to extract and report the actual count.",1.0,"The answer is incomplete. The question asks for a specific number ('How many'), but the LLM Output does not provide this number. Instead, it provides a link for the user to find the answer themselves, which does not fulfill the requirement of answering the question.",2.0,"The output includes multiple tool calls and explanations of the process, which adds some verbosity. However, the main narrative is reasonably structured. The issue is that it provides process details and a link rather than the direct answer, making it somewhat indirect.",3.0,"The LLM Output relies entirely on information retrieved from the cBioPortal database through the tool calls. It correctly identifies the study, uses the SAMPLE_TYPE attribute from the database, and provides URLs based on the retrieved data. No external information or hallucinations are present.",110001,703,21.888691901927814,,
What treatment did most patients receive in the MSK-CHORD Study?,1.0,"The LLM Output does not provide the actual answer to the question. It navigates to the study page but fails to extract or report what treatment most patients received. The expected answer shows a specific URL, suggesting there should be accessible treatment data, but the LLM did not retrieve or present this information.",1.0,"The output is incomplete as it does not answer the core question about which treatment most patients received. Instead, it only provides navigation instructions and general guidance on where to find treatment information, without actually delivering the requested data.",2.0,"While the output provides clear navigation steps, it is somewhat verbose given that it doesn't actually answer the question. The detailed instructions about how to find treatment information are unnecessary if the system could have directly retrieved and presented the answer.",3.0,"The output faithfully uses only the information from the cbioportal database context. It correctly identifies the study, provides accurate metadata (25,040 samples, study name), and doesn't introduce external information or hallucinations. However, it fails to extract the specific treatment data that appears to be available in the source.",65011,428,12.951582725974731,,
What are the top 5 most frequently mutated genes in the Osteosarcoma study from TARGET?,1.0,"The LLM Output does not provide the actual list of the top 5 most frequently mutated genes. It only navigates to the study page and describes where to find the information, but fails to extract and present the specific gene names that answer the question.",1.0,"The answer is incomplete. The question explicitly asks for the top 5 most frequently mutated genes, but the LLM only provides a link to the study page and instructions on how to find the information. It does not deliver the actual list of genes, which is the core requirement of the question.",2.0,"The output is somewhat verbose. While it provides useful context about navigating to the study, it includes unnecessary details about how to use the interface and what other data types are available, when the question simply asks for a list of 5 genes.",3.0,"The LLM Output is faithful to the context provided. It correctly identifies the study (os_target_gdc), uses the information from the database query results, and provides the appropriate study URL. It does not introduce information from outside sources or hallucinate data.",64829,465,12.493146421038546,,
What percentage of colorectal cancer samples have KRAS mutations in the MSK-CHORD Study?,1.0,"The LLM Output does not provide the actual percentage requested. It only provides links and instructions on how to find the information, but does not state the specific percentage value. The expected answer URLs suggest the information exists in cBioPortal, but the LLM failed to retrieve or report it.",1.0,"The answer is incomplete. The question asks for a specific percentage value, but the LLM Output only provides navigation links and instructions for how the user could find the answer themselves. It does not actually answer the question with the requested percentage.",2.0,"While the output is structured, it is somewhat verbose for a question that requires a simple numerical answer. The LLM provides detailed navigation instructions and multiple ways to access the data, when the user simply wanted the percentage value itself.",3.0,"The LLM Output relies on the cBioPortal database context provided and uses the appropriate tools to navigate to the MSK-CHORD study. It does not introduce information from outside sources or hallucinate data. However, it fails to extract the actual answer from the available data.",65166,513,13.08633429207839,,
Do patients with PIK3CA mutations have different overall survival outcomes compared to PIK3CA wild-type patients in breast cancer from the MSK-CHORD Study?,2.0,"The LLM correctly identifies the MSK-CHORD study and provides a valid approach to analyze PIK3CA mutations. However, the generated URL differs from the expected answer URL (different domain: deploy-preview-5312--cbioportalfrontend.netlify.app vs www.cbioportal.org, and different parameters). The expected URL appears to be a comparison page with a session_id, while the LLM provides a results/survival page. The LLM also correctly notes that MSK-CHORD is a pan-cancer study requiring breast cancer filtering, which is accurate.",2.0,"The LLM provides a functional link to analyze PIK3CA survival data and explains the approach well. However, it doesn't directly answer whether there IS a difference in survival outcomes - it only provides the tools to investigate this question. The expected answer suggests a specific comparison page that may already show the results, while the LLM's answer requires the user to perform additional filtering and interpretation. The LLM acknowledges this limitation and offers alternative approaches.",2.0,"The output includes extensive explanatory notes, alternative approaches, and step-by-step reasoning that, while helpful, makes the response somewhat verbose. The core answer (the survival analysis link) could have been provided more directly. However, the additional context about the pan-cancer nature of the study and filtering requirements is relevant and useful.",3.0,"The LLM Output relies entirely on information retrieved from the cbioportal database through the tool calls. All study information, clinical attributes, and cancer types are directly sourced from the API responses. The LLM does not introduce external knowledge or hallucinate information - it accurately reports what it finds in the database and acknowledges limitations when the exact expected result cannot be reproduced.",133672,1095,29.942965397029184,,
,,,,,,,,,111703,1331,26.53119944408536,Invalid JSON,"{
  ""question"": ""What is the correlation between tumor mutational burden and microsatellite instability status in colorectal cancer patients from the MSK-CHORD Study?"",
  ""correctness_score"": 2,
  ""correctness_explanation"": ""The LLM Output generates a URL that is mostly correct but uses different parameters than the expected answer. The expected answer uses 'MSI_SCORE' for the vertical axis, while the LLM uses 'MSI_TYPE' for the horizontal axis and 'TMB_NONSYNONYMOUS' for the vertical axis. Additionally, the expected URL uses 'plots_horz_selection' for TMB and 'plots_vert_selection' for MSI_SCORE, which is the opposite orientation. The LLM also uses a different base URL (deploy-preview-5312 vs www.cbioportal.org). While the approach is valid and would show a correlation, it doesn't match the expected configuration exactly."",
  ""completeness_score"": 3,
  ""completeness_explanation"": ""The LLM Output fully addresses the question by providing a working link to visualize the correlation between TMB and MSI status in colorectal cancer patients from the MSK-CHORD study. It successfully filters for colorectal cancer patients and sets up a plot comparing the two variables. The output also provides helpful context about what to expect and additional analysis options."",
  ""conciseness_score"": 2,
  ""conciseness_explanation"": ""While the output provides the necessary information and link, it includes extensive additional commentary about what the user will see, expected biological relationships, and additional analysis options. This extra information, while potentially helpful, makes the response somewhat verbose when the core answer is simply the URL to the correlation plot."",
  ""faithfulness_score"": 3,
  ""faithfulness_explanation"": ""The LLM Output relies entirely on information retrieved from the cbioportal database through the tool calls. It correctly identifies the study (msk_chord_2024), uses available clinical attributes (MSI_TYPE, TMB_NONSYNONYMOUS, CANCER_TYPE), and filters appropriately based on the data returned from the API calls. The biological interpretation about MSI-H"
How does the mutation landscape differ between primary and metastatic samples from the same patients in the MSK-CHORD Study?,2.0,"The LLM correctly identifies the MSK-CHORD study and the SAMPLE_TYPE attribute with Primary and Metastasis values. However, it doesn't actually answer the question about differences in mutation landscape - it only provides links to filtered views. The expected answer indicates this comparison is 'Not possible in UI (??)', suggesting the LLM's approach of providing separate filtered views doesn't truly address comparing samples from the SAME patients.",1.0,"The output does not complete the task. The question specifically asks about comparing primary and metastatic samples from the SAME patients (paired samples), but the LLM only provides separate filtered views of all primary samples vs all metastatic samples across different patients. This is a fundamentally different analysis. The expected answer 'Not possible in UI (??)' suggests this paired comparison cannot be done through the cBioPortal UI, which the LLM failed to recognize or communicate.",2.0,"The output is somewhat verbose with detailed instructions on how to manually compare the views, when it should have more directly addressed whether this specific type of paired sample comparison is possible in the UI. The step-by-step comparison instructions are helpful but don't address the core limitation.",3.0,"The LLM relies entirely on information from the cBioPortal database queries and doesn't introduce external information. All study details, clinical attributes, and URLs are derived from the API responses.",113159,1258,27.256286283023655,,
Which cancer types have the highest frequency of EGFR mutations across all TCGA Pan-Cancer Atlas studies?,2.0,"The LLM output provides a valid URL to query EGFR mutations across TCGA Pan-Cancer Atlas studies, but it does not directly answer which cancer types have the highest frequencies. It only provides expectations based on 'published literature' (LUAD 10-15%, GBM with amplifications/mutations, HNSC moderate, COADREAD lower) rather than actual data from the cBioPortal query. The expected answer URL includes a 'cancerTypesSummary' view which would directly show the frequencies, while the LLM's URL defaults to the 'oncoprint' view.",2.0,"The output provides a URL to access the data and instructions on how to navigate to find the answer (via the Cancer Types Summary tab), but it does not directly provide the answer to which cancer types have the highest EGFR mutation frequencies. The user would still need to click through and view the data themselves. A complete answer would include the actual frequencies or at least direct the user to the cancerTypesSummary view that the expected answer uses.",2.0,"The output includes helpful navigation instructions and context, but is somewhat verbose with multiple sections explaining what the user will see, how to navigate, and expected results. The core answer (the URL and instruction to check Cancer Types Summary tab) could have been delivered more directly.",2.0,"The output relies partially on external knowledge when it states 'Based on published literature, you should expect to see the highest EGFR mutation frequencies in...' with specific percentages (10-15% for LUAD). This information is not derived from the cBioPortal context/source provided. The URL generation and navigation instructions are faithful to the cBioPortal system, but the specific mutation frequency predictions come from outside sources.",84081,1744,24.894865765003487,,
What is the correlation between EGFR mRNA expression and EGFR protein levels in ovarian cancer samples?,2.0,"The LLM output provides a URL to visualize the correlation, but the URL domain differs from the expected answer. The expected answer uses 'www.cbioportal.org' while the LLM output uses 'deploy-preview-5312--cbioportalfrontend.netlify.app'. Additionally, the URL structure and parameters differ slightly (e.g., the LLM uses 'study/plots?id=' while the expected uses 'results/plots?cancer_study_list='). The core functionality appears similar but the technical implementation differs.",3.0,"The output fully addresses the question by identifying the appropriate ovarian cancer study (TCGA PanCancer Atlas), explaining that it contains both mRNA and protein data, and providing a direct link to visualize the correlation between EGFR mRNA expression and protein levels. It also explains what the user will see in the plot (correlation coefficients, data points, regression line).",2.0,"The output is somewhat verbose. While the explanation of the study selection and data types is helpful, there is considerable detail about the tool calls, study metadata, and multiple alternative studies that could be condensed. The core answer (the URL and brief explanation) could be delivered more directly.",3.0,"The LLM output relies entirely on the cbioportal database context provided. It uses the resolve_and_route tool to search for ovarian cancer studies, selects an appropriate study from the returned results, and constructs a URL to the plots page with the correct parameters for EGFR mRNA and protein correlation. All information is traceable to the tool responses and the cbioportal database structure.",73432,952,17.451175582013093,,
Is BRCA1 promoter methylation associated with decreased BRCA1 mRNA expression in ovarian cancer?,2.0,"The LLM output provides a methodologically correct approach to answering the question by directing to a plots page that would show the correlation between BRCA1 methylation and expression. However, the generated URL differs from the expected answer URL in key parameters: the LLM uses generic 'BRCA1' gene selection for methylation instead of the specific probe 'cg04658354', and uses 'ov_tcga_pan_can_atlas_2018_rna_seq_v2_mrna_median_Zscores' instead of 'MRNA_EXPRESSION' with gene ID 672. The expected URL also uses log scale for both axes, which the LLM's URL does not specify.",3.0,"The output fully addresses the question by providing a link to visualize the relationship between BRCA1 methylation and expression in ovarian cancer, explaining what to look for in the results (negative correlation), and providing additional guidance on how to interpret and further analyze the data.",2.0,"While the output is generally well-structured, it includes somewhat verbose explanations about what to look for and additional analysis options. The detailed breakdown of the study selection process and multiple paragraphs of guidance, while helpful, make the response longer than strictly necessary to answer the core question.",3.0,"The output relies entirely on the cBioPortal database context provided. It uses the study metadata returned from the tool calls, correctly identifies available molecular profiles, and constructs a URL based on the available data types in the system. No external knowledge or hallucinated information is introduced.",71157,1076,18.9549116010312,,
"What are the survival differences between EGFR-mutated, EGFR-amplified, and EGFR wild-type lung adenocarcinoma patients?",2.0,"The LLM correctly identifies the appropriate study (TCGA PanCancer Atlas) and generates a valid cBioPortal URL for survival analysis. However, the generated URL differs from the expected answer in important ways: it lacks the specific comparison groups parameter and doesn't explicitly separate EGFR mutations from amplifications in the URL structure. The expected URL includes 'profileFilter=mutations%2Cgistic' and 'comparison_selectedGroups' parameters that ensure proper grouping of the three patient categories.",2.0,"The output provides a functional link to survival analysis and explains what users will see, but it doesn't fully address the question as asked. The user asked for the actual survival differences (the results), but the LLM only provides a link to where those differences can be viewed. The generated URL also doesn't guarantee the three-way comparison (mutated vs. amplified vs. wild-type) that the question specifically requests, as it may default to a simpler altered vs. unaltered comparison.",2.0,"The output includes helpful context about the study selection and usage instructions, but is somewhat verbose with extensive formatting, multiple sections, and detailed explanations that go beyond what's necessary to answer the question. The step-by-step tool calling results and extensive 'How to Use' section add unnecessary length.",3.0,The LLM output relies entirely on the cBioPortal database context provided. It uses the study metadata returned from the tool calls and generates URLs based on cBioPortal's structure. No external information or hallucinations are present; all content is traceable to the cBioPortal source.,71054,831,23.853713877033442,,
How does PTEN alteration (mutations or homozygous deletions) affect pAKT protein levels in lung squamous cell carcinoma?,2.0,"The LLM provides a biologically accurate explanation of the PTEN-AKT relationship and correctly identifies the relevant study (TCGA Lung Squamous Cell Carcinoma). However, it provides a URL to the oncoprint view rather than the comparison/protein view that is shown in the expected answer. The expected answer points to a specific comparison analysis URL that directly shows the protein level comparison, while the LLM's URL goes to a different view requiring additional navigation steps.",2.0,"The answer provides guidance on how to analyze the relationship between PTEN alterations and pAKT levels, including navigation instructions and biological context. However, it doesn't directly provide the comparison analysis that the expected answer shows. The LLM gives a workaround approach (using Plots tab) rather than the direct comparison view that would immediately answer the question. Due to the service error, it couldn't complete the actual analysis.",2.0,"The output includes relevant information but is somewhat verbose. It provides extensive background on the biological relationship and multiple navigation options when a more direct answer pointing to the comparison view would be more concise. The biological explanation, while accurate, adds length that may not be necessary for simply answering how to access the data.",2.0,"The LLM relies on its knowledge of cBioPortal functionality and the PTEN-AKT biological pathway rather than strictly using the provided context (which only shows an expected answer URL). While the biological information is accurate, it represents external knowledge not present in the context. The LLM also makes assumptions about what analysis approach to use rather than directly matching the expected answer's comparison view approach.",42735,830,36.10466902400367,,
What percentage of endometrial cancer patients have co-occurring oncogenic mutations in both KRAS and NRAS?,1.0,"The LLM Output does not provide the actual percentage requested. While it correctly identifies the study and provides a URL to access the information, it fails to deliver the numerical answer. The expected answer URL points to a mutual exclusivity analysis page that would contain the specific percentage, but the LLM did not retrieve or report this data.",1.0,"The answer is incomplete as it does not provide the specific percentage requested in the question. The LLM encountered API errors and instead provided guidance on how to find the information manually, but did not actually answer the question. The user asked for a specific numerical value (percentage), which was not provided.",2.0,"The output is somewhat verbose. While the explanation of the API errors and the guidance provided has some value, much of it is unnecessary for answering the specific question. The background information about KRAS/NRAS mutual exclusivity and the step-by-step navigation instructions add length without providing the requested answer.",2.0,"The LLM Output includes some external knowledge not directly from the cBioPortal database context. Specifically, the statement about KRAS and NRAS mutations being 'typically mutually exclusive' in most cancer types and activating the same RAS/MAPK pathway appears to be general oncology knowledge rather than information retrieved from the cBioPortal source. However, the study identification and URL construction appear to be appropriate attempts to access the source.",64600,665,32.41828847397119,,
What percentage of endometrial cancer samples have hypermutation (>5000 mutations) and how does this correlate with histological subtype?,1.0,The LLM Output does not provide the actual answer to the question. It navigates to a study page but fails to extract or calculate the percentage of samples with >5000 mutations or provide any correlation data with histological subtypes. The expected answer shows a specific comparison analysis that should have been performed.,1.0,"The output is incomplete as it only provides navigation instructions and general guidance on how to perform the analysis, rather than actually answering the specific question about the percentage and correlation. The user asked for specific data (percentage and correlation), but received only a study link and analysis suggestions.",1.0,"The output is excessively verbose, providing extensive background information, multiple analysis options, and general context about endometrial cancer subtypes when the user asked for a specific quantitative answer. The response includes unnecessary details about various study options and step-by-step instructions that don't directly answer the question.",2.0,"While the LLM correctly uses the cbioportal database as specified in the context, it includes external knowledge about endometrial cancer molecular subtypes, POLE mutations, MSI status, and mutation patterns that weren't derived from the specific query results. The expected answer URL suggests a specific comparison analysis should have been performed, which the LLM did not execute.",72849,836,39.15996382199228,,
Which cancer types show the highest frequency of BRAF V600E mutations across all TCGA Pan-Cancer Atlas studies?,2.0,"The LLM provides generally accurate information about BRAF V600E frequencies in different cancer types (thyroid ~60-80%, melanoma ~40-50%, colorectal ~8-10%, lung adenocarcinoma ~1-3%). However, these are presented as general knowledge rather than specific TCGA Pan-Cancer Atlas data, and the actual answer should have been derived from the cBioPortal query results.",1.0,"The LLM failed to answer the question due to a service error (503). Instead of providing the specific cancer types with highest BRAF V600E frequency from TCGA Pan-Cancer Atlas studies, it only offered general guidance on how to find the answer and provided approximate frequencies from published literature. The expected answer shows a specific cBioPortal query URL that would display the actual data, which the LLM did not successfully generate or access.",2.0,"The output is somewhat verbose, providing extensive guidance on alternative approaches and navigation paths when the primary task was to identify specific cancer types with highest BRAF V600E frequencies. While the troubleshooting information may be helpful, it detracts from directly answering the question.",1.0,"The LLM relied heavily on external knowledge rather than the cBioPortal database as specified in the Context/Source. The frequency percentages provided (thyroid 60-80%, melanoma 40-50%, etc.) are stated as 'based on published TCGA Pan-Cancer Atlas data' but were not actually retrieved from the cBioPortal database. The expected answer shows a specific cBioPortal URL that should have been generated, but the LLM instead provided general literature-based information.",42687,573,13.2836520280689,,
,,,,,,,,,80951,1935,28.676698158029467,Invalid JSON,"{
  ""question"": ""Which cancer types have the highest aneuploidy scores and how does this correlate with mutation burden across TCGA Pan-Cancer studies?"",
  ""correctness_score"": 2,
  ""correctness_explanation"": ""The LLM output provides a technically correct approach to answering the question by generating a URL to visualize aneuploidy scores vs mutation burden. However, it doesn't actually answer which cancer types have the highest aneuploidy scores - it only provides the tools to explore this. The expected answer URL shows a different configuration (CANCER_TYPE on x-axis, ANEUPLOIDY_SCORE on y-axis) compared to what the LLM generated (TMB_NONSYNONYMOUS on x-axis, ANEUPLOIDY_SCORE on y-axis), suggesting the LLM may have misinterpreted the optimal visualization approach."",
  ""completeness_score"": 2,
  ""completeness_explanation"": ""The output is partially complete. It successfully provides a way to explore the data and includes 16 cancer types, but it doesn't actually answer the core question of which cancer types have the highest aneuploidy scores. The expected answer includes all 32 TCGA Pan-Cancer Atlas studies, while the LLM only included 16. The output mentions 'Expected Patterns' based on literature but this section is incomplete (cuts off mid-sentence)."",
  ""conciseness_score"": 2,
  ""conciseness_explanation"": ""The output is somewhat verbose. While the structured format with sections is helpful, there's considerable repetition (listing all 16 cancer types with sample counts twice, extensive explanation of the approach). The incomplete 'Expected Patterns' section adds unnecessary length without value. A more direct answer identifying the cancer types with highest aneuploidy scores would be more concise."",
  ""faithfulness_score"": 2,
  ""faithfulness_explanation"": ""The output mostly relies on the cBioPortal database context, correctly using the available clinical attributes (ANEUPLOIDY_SCORE, TMB_NONSYNONYMOUS) from the API response. However, the 'Expected Patterns (Based on Literature)' section introduces external knowledge not present in"
What fraction of patients were older than five when diagnosed according to the Pediatric Neuroblastoma study from TARGET?,1.0,"The LLM Output does not provide the actual fraction or percentage of patients older than 5 years at diagnosis. It only provides links and instructions for the user to calculate this themselves, which does not answer the question. The expected answer shows a specific URL that presumably contains this information, but the LLM failed to extract and present the actual numerical answer.",1.0,"The answer is incomplete. While the LLM successfully identified the correct study (nbl_target_2018_pub with 1,089 samples) and retrieved age data, it failed to provide the actual fraction requested. Instead, it redirected the user to explore the data themselves. A complete answer would state something like 'X out of 1,089 patients (Y%) were older than 5 years at diagnosis.'",2.0,"The output is somewhat verbose. It includes multiple tool calls and explanations of the process, along with two different URLs and instructions for what the user will see. A more concise answer would simply state the fraction directly after retrieving the necessary data.",3.0,"The LLM Output relies entirely on data retrieved from the cbioportal database through the tool calls. The study ID (nbl_target_2018_pub), sample count (1,089), and age values are all traceable to the API responses. No external information or hallucinations are present.",87853,750,19.314500399981625,,
What is the most frequent mutation in the TP53 gene in the TCGA breast cancer study?,2.0,"The LLM Output correctly navigates to the appropriate cBioPortal page and provides accurate information about where to find TP53 mutations. However, it does not actually answer the specific question asked - it doesn't identify which specific mutation is most frequent. It only explains what the user will see on the page (e.g., 'mutations commonly found in hotspot regions, particularly in the DNA-binding domain (codons 175, 248, 273, etc.)'). The expected answer shows a direct link to the mutations page, suggesting the answer requires viewing the actual data.",2.0,"The output provides a comprehensive guide to accessing the mutations data and explains what information will be available, but it does not directly answer the question about which specific mutation is most frequent. It directs the user to where they can find the answer rather than providing the answer itself. A complete answer would state something like 'The most frequent mutation is R175H' (or whatever the actual most frequent mutation is).",2.0,"The output is somewhat verbose. While the detailed explanation of what the user will see on the mutations page is helpful, it includes extensive background information about the study selection process and detailed descriptions of the interface elements that go beyond what's necessary to answer the specific question. A more concise answer would navigate to the page and state the most frequent mutation directly.",3.0,"The output faithfully uses the cBioPortal database as specified in the context. All information about the TCGA studies, navigation, and what data is available comes from the tool calls and their results. The general statements about TP53 hotspot mutations (codons 175, 248, 273) are common knowledge in cancer genomics but are presented as examples of what might be found rather than definitive claims.",75042,668,16.448015002999455,,
How many patients have an EGFR amplification in the TCGA Lung Adenocarcinoma study?,2.0,"The LLM correctly identifies the appropriate TCGA Lung Adenocarcinoma study (PanCancer Atlas) and provides a valid link to view EGFR alterations. However, it does not provide the actual number of patients with EGFR amplifications, which is what the question specifically asks for. The expected answer URL suggests the information should be directly accessible.",1.0,"The output does not answer the specific question asked. The user wants to know 'how many patients' have EGFR amplification, but the LLM only provides a link and instructions on how to find this information themselves. It does not retrieve or state the actual count of patients with EGFR amplifications.",2.0,"The output is somewhat verbose. While it provides helpful context about the different TCGA studies and navigation instructions, it could be more direct. The extensive explanation about how to interpret the OncoPrint and the offer to provide links to other studies adds unnecessary length when the user simply wants a number.",3.0,"The LLM output is faithful to the cBioPortal database context. It uses the tool results provided, correctly identifies the available studies from the database, and generates appropriate links based on the returned data. It does not introduce information from outside the provided context.",70952,649,14.734101967071183,,
,,,,,,,,,69600,646,14.643722858978435,Invalid JSON,"{
  ""question"": ""Which KRAS mutations are most common in colorectal cancer?"",
  ""correctness_score"": 3,
  ""correctness_explanation"": ""The LLM output correctly identifies that KRAS mutations occur at codons 12, 13, and 61, with specific mutations like G12D, G12V, and G13D being most common. This is factually accurate for colorectal cancer. The output also correctly navigates to the appropriate cBioPortal study (PanCancer Atlas) and generates a valid URL to view the mutation data."",
  ""completeness_score"": 2,
  ""completeness_explanation"": ""While the LLM provides a link to view the KRAS mutations and mentions the most common mutation types (G12D, G12V, G13D), it doesn't actually display the specific mutation frequencies or data from the database. The expected answer shows a direct link to the mutations page, which the LLM does provide (albeit to a different deployment URL). However, the user asked 'which mutations are most common' and the LLM describes what they will find rather than presenting the actual data."",
  ""conciseness_score"": 2,
  ""conciseness_explanation"": ""The output is somewhat verbose. It includes detailed explanations about the tool selection process, multiple study options, and extensive descriptions of what the user will see on the page. While informative, much of this could be condensed. The core answer about common KRAS mutations (G12D, G12V, G13D at codons 12, 13, and 61) could have been stated more directly."",
  ""faithfulness_score"": 3,
  ""faithfulness_explanation"": ""The LLM output is faithful to the context provided. It uses the cBioPortal database as specified, navigates to the appropriate colorectal cancer study, and generates a URL to view KRAS mutations. The mention of common mutations (G12D, G12V, G13D) is general knowledge about KRAS in colorectal cancer that would be visible in the cBioPortal data, though the LLM appropriately frames this as 'key findings you can expect' rather than"
What is the median survival time in the Pediatric Neuroblastoma study from TARGET?,1.0,"The LLM Output does not provide the actual median survival time value. It only provides links to study pages and instructions on how to find the information, but does not answer the specific question asked. The expected answer shows a link to a specific study (os_target_gdc), but the LLM navigated to a different study (nbl_target_2018_pub).",1.0,"The output fails to provide the median survival time, which is the core information requested. Instead, it only provides navigation instructions and study links. The user asked for a specific numerical value (median survival time), but the LLM did not retrieve or provide this data.",1.0,"The output is excessively verbose, providing detailed navigation instructions, multiple study options, and step-by-step guidance on how to find the information manually, when the question simply asked for the median survival time value. The response could have been much more direct.",2.0,"The LLM correctly uses the cbioportal database as specified in the context and retrieves actual study information from the database. However, it provides instructions and assumptions about what the user will find (e.g., 'the survival curve will display the median survival time') without actually retrieving that data from the source, which represents some speculation beyond what was directly obtained from the database.",66019,503,13.313731409027241,,
How does methylation of the MGMT gene promoter affect the prognosis and treatment response in patients with glioblastoma?,2.0,"The LLM provides generally accurate information about MGMT methylation's clinical significance (better prognosis, increased sensitivity to temozolomide). However, it directs the user to a study view page rather than the expected comparison/survival analysis page. The expected answer is a specific comparison URL showing survival analysis results, not a general study view.",2.0,"The output provides helpful context about MGMT methylation and instructions on how to explore the data, but it doesn't directly answer the question about how methylation affects prognosis and treatment response with actual data or results. It provides a pathway to find the answer rather than the answer itself. The expected answer appears to be a direct link to a survival comparison showing the actual effect.",1.0,"The output is excessively verbose with extensive background information, multiple sections, and detailed instructions on how to use cBioPortal. For a question asking about the effect of MGMT methylation, a more direct answer showing or linking to the actual survival/treatment response data would be more appropriate. The output includes unnecessary disclaimers and extensive tutorial-style content.",2.0,"While the LLM correctly uses the cBioPortal database context, it adds substantial external knowledge about MGMT methylation's clinical significance (prognostic value, predictive value, treatment decisions, temozolomide sensitivity) that isn't explicitly shown in the provided context. The context shows available studies and their metadata, but the clinical interpretation of MGMT methylation appears to come from the LLM's training data rather than the provided source.",70805,921,20.429660528083332,,
For patients with the EML4-ALK fusion gene in lung cancer how do the different fusion variants affect their long-term quality of life and risk of developing a secondary cancer?,3.0,The LLM correctly identifies that this question is out of scope for cBioPortal. It accurately explains that cBioPortal contains genomic and survival data but not quality of life metrics or comprehensive secondary cancer development data. The information about what can and cannot be explored in cBioPortal is factually accurate.,3.0,"The output fully addresses the question by clearly explaining why it cannot be answered using cBioPortal data. It explicitly states what data is available (genomic alterations, survival data) versus what is not (quality of life metrics, secondary cancer risk), which directly responds to the user's query about these specific outcomes.",1.0,"The output is excessively verbose. While the question is out of scope and should be answered with a brief explanation, the LLM provides extensive details about multiple studies, creates navigation links, searches through databases, and offers alternative exploration options. For an out-of-scope question, a simple explanation of why the data is not available would suffice.",3.0,"The output is faithful to the cBioPortal database context. It correctly identifies available studies, their sample counts, and molecular profile types based on the database queries. The limitations described (lack of quality of life data and secondary cancer information) are accurate reflections of what genomic databases typically contain.",95912,1314,28.466078158002347,,
"In the ""Pan-cancer analysis of whole genomes"" study what is the survival difference and the corresponding statistical significance between patients with mutations in both TP53 and KRAS versus patients with only a KRAS mutation?",1.0,"The LLM Output does not provide the actual survival difference or statistical significance values that were requested. It only provides instructions on how to find this information, rather than the actual answer. The expected answer shows a direct comparison URL that would contain these specific values, but the LLM failed to generate or access this comparison.",1.0,"The answer is incomplete. The question explicitly asks for two specific pieces of information: (1) the survival difference and (2) the corresponding statistical significance (p-value). The LLM Output provides neither of these values. Instead, it provides filtered study view URLs and instructions on how the user could find this information themselves, which does not answer the question.",1.0,"The output is excessively verbose. It provides lengthy explanations, multiple URLs, and step-by-step instructions when the question simply asked for two specific numerical values (survival difference and p-value). The response includes unnecessary alternative approaches and detailed navigation instructions that don't contribute to answering the specific question asked.",2.0,"While the LLM correctly identifies the study from cBioPortal and uses appropriate tools to generate filtered views, it fails to actually access the comparison URL provided in the expected answer (https://www.cbioportal.org/comparison/survival?comparisonId=691f3fd9b2bb32147b013ee9) which would contain the requested survival statistics. The LLM appears to have the capability to navigate to comparison pages but did not do so, instead providing workaround instructions that don't directly answer the question.",66210,1153,18.695337216951884,,
Are there studies that were not processed using polyA enrichment in order to explore lncRNA-related questions?,1.0,"The expected answer indicates this question is 'Out of scope' for cBioPortal, meaning it cannot be answered using the database. However, the LLM provides a detailed response attempting to answer the question, which is factually incorrect given the scope limitation. The LLM correctly identifies that cBioPortal doesn't include library preparation metadata, but then proceeds to suggest studies and approaches, which contradicts the out-of-scope nature of the query.",1.0,"The LLM fails to recognize that this question is out of scope for cBioPortal. Instead of clearly stating that this type of technical library preparation information is not available in the database and cannot be answered, it provides extensive suggestions and workarounds. A complete answer should have acknowledged the limitation and directed the user to appropriate alternative resources without attempting to answer within cBioPortal.",1.0,"The output is excessively verbose, providing multiple sections with study links, alternative approaches, and detailed suggestions when the appropriate response should have been a concise statement that this information is not available in cBioPortal. The response includes unnecessary details about specific studies, TCGA data, and alternative resources that go far beyond what's needed.",2.0,"While the LLM does use information from the context (the list of studies returned by the tool), it goes beyond the provided context by making assumptions about TCGA studies having both polyA and total RNA-seq data, suggesting alternative resources like ENCODE and FANTOM, and providing guidance about checking publications. The LLM also fails to recognize the 'Out of scope' designation that should have been evident from the expected answer format.",48506,708,16.903311001020484,,
In the Breast Invasive Carcinoma TCGA study what are the top 5 down-regulated genes in TP53 mutated samples compared to non-mutated ones?,1.0,"The LLM Output does not provide the actual top 5 down-regulated genes as requested. Instead, it only provides navigation instructions to access a comparison page. The expected answer shows a direct link to the mRNA comparison results, but the LLM failed to retrieve or display the actual gene list.",1.0,"The answer is incomplete as it does not provide the specific top 5 down-regulated genes that were requested. It only explains how to navigate to find this information, rather than actually answering the question with the gene names.",1.0,"The output is excessively verbose, providing detailed navigation instructions, multiple study options, extensive metadata, and step-by-step guidance when the question simply asked for a list of 5 genes. The response includes unnecessary technical details about study selection and comparison setup.",3.0,The LLM Output relies entirely on the cBioPortal database context provided through the tool calls. It correctly identifies the appropriate TCGA breast cancer study and attempts to navigate to the comparison view using only information from the database. No external knowledge or hallucinations are present.,102341,918,21.21630372502841,,
In the Pediatric Neuroblastoma study from TARGET what is the survival difference and the corresponding statistical significance between patients who were older than four when diagnosed and the younger ones?,1.0,"The LLM Output does not provide the actual survival difference or statistical significance values that were requested. The expected answer shows a direct link to a comparison with specific survival statistics, but the LLM only provides filtered cohort links without the actual numerical results (p-values, median survival times, hazard ratios).",1.0,"The answer is incomplete. The question explicitly asks for 'the survival difference and the corresponding statistical significance,' but the LLM Output only provides links to filtered cohorts and instructions on how to perform the comparison manually. It does not provide the actual survival statistics or p-values that answer the question.",2.0,"The output includes some unnecessary information such as general background about neuroblastoma prognosis and detailed step-by-step instructions. While these may be helpful, they add verbosity when the user specifically asked for survival difference and statistical significance values.",3.0,"The LLM Output relies on information from the cbioportal database as specified in the context. It correctly identifies the TARGET neuroblastoma study, uses appropriate clinical attributes (AGE), and creates valid filtered cohorts. The statement about age 4 being a clinically relevant cutoff is general medical knowledge but doesn't constitute a hallucination in this context.",142235,1433,31.160106876981445,,
In the TCGA Glioblastoma multiforme study compare the median patient age at diagnosis between patients with IDH1 R132H mutation and patients with wild-type IDH1.,1.0,"The LLM Output does not provide the actual median ages for comparison, which is what the question asks for. The expected answer shows a direct comparison link that would display the median ages, but the LLM failed to generate this comparison and instead provided workarounds without delivering the actual numerical answer.",1.0,"The output completely fails to answer the question. It does not provide the median ages for either the IDH1 R132H mutated group or the wild-type IDH1 group. Instead, it explains technical difficulties and suggests manual workarounds, leaving the user without the requested comparison data.",1.0,"The output is excessively verbose, providing lengthy explanations about technical issues, multiple alternative approaches, and detailed step-by-step instructions for manual analysis. It includes unnecessary information about different TCGA studies and troubleshooting steps rather than directly answering the question.",3.0,"The output faithfully attempts to use the cbioportal database as specified in the context. All the study IDs, molecular profile IDs, and URLs referenced are derived from the tool responses. The LLM does not introduce external information or hallucinate data, though it fails to complete the task successfully.",98499,1189,23.68327242601663,,
"In breast cancer, what is the correlation coefficient between EGFR expression levels and PIK3CA mutation status considering only patients who also have a homozygous deletion of PTEN?",2.0,"The LLM correctly identifies the appropriate study (TCGA PanCancer Atlas) and correctly sets up the filter for PTEN homozygous deletions. However, it does not provide the actual correlation coefficient value that the question asks for. Instead, it provides instructions on how to obtain it, which is not what was requested.",1.0,"The output does not answer the specific question asked. The user requested a correlation coefficient value, but the LLM only provides a filtered URL and instructions for how the user could calculate it themselves. The expected answer shows a direct URL with all parameters configured (including EGFR expression and PIK3CA mutation settings), but the LLM's output only filters for PTEN deletions without configuring the plot axes.",1.0,"The output is excessively verbose. It includes lengthy explanations about multiple options, detailed step-by-step instructions, and alternative approaches when the question simply asked for a correlation coefficient. The response could have been much more direct.",3.0,"The LLM's output is faithful to the cBioPortal database context. It correctly uses the study information, properly constructs the filter for PTEN homozygous deletions, and accurately describes cBioPortal's capabilities and limitations. It does not introduce information from outside the provided context.",100362,1208,26.938779094954953,,
Can you identify a mutations that are highly specific to a single cancer type?,3.0,"The LLM Output provides factually accurate information about cancer type-specific mutations. The examples given (BRAF V600E in melanoma and thyroid cancer, IDH1 R132H in glioma) are well-documented and correct. The approach using pan-cancer studies from TCGA PanCancer Atlas is appropriate and accurate.",2.0,"The output addresses the question by demonstrating how to identify cancer type-specific mutations using cBioPortal, and provides concrete examples. However, the expected answer indicates this may not be fully possible in the UI, and the output doesn't explicitly acknowledge this limitation. The output shows a workaround approach rather than directly answering whether the UI supports this specific analysis natively.",2.0,"The output is somewhat verbose with extensive formatting, multiple sections, and detailed step-by-step instructions. While comprehensive, it could be more direct in answering the core question. The inclusion of a full table of examples and multiple navigation attempts adds length that may not be strictly necessary.",3.0,"The output relies entirely on the cBioPortal database context. All study IDs, cancer types, and navigation approaches are derived from the tool responses and cBioPortal's actual structure. The examples of cancer-specific mutations (BRAF V600E, IDH1 R132H) are well-established in the cancer genomics literature and appropriate for demonstrating the concept within cBioPortal's framework.",115255,2535,34.190822707954794,,
In the TCGA Breast Cancer study if a patient has both a PIK3CA mutation and a PTEN deletion what is their probability of having a luminal A subtype? Is this probability different from a patient with only a PIK3CA mutation?,2.0,"The LLM correctly identifies that cBioPortal doesn't directly calculate conditional probabilities and provides a reasonable approach to manually calculate them. However, it uses the wrong study (brca_tcga_pub from 2012) instead of the PanCancer Atlas study (brca_tcga_pan_can_atlas_2018) that is specified in the expected answer URL. The PanCancer Atlas study has a 'SUBTYPE' clinical attribute that likely contains PAM50 classifications including Luminal A. The approach is methodologically sound, but the study selection is incorrect.",2.0,"The output provides a comprehensive methodology for answering the question but doesn't provide the actual numerical probabilities requested. It gives users the tools and links to calculate the probabilities themselves, but stops short of providing the specific answer. The expected answer URL suggests there's a comparison view that would show the actual statistics, which the LLM doesn't fully replicate or extract.",2.0,"The output is somewhat verbose with multiple sections, alternative approaches, and extensive explanations. While the information is useful, it could be more direct. The inclusion of both StudyView and OncoPrint approaches, plus detailed step-by-step instructions, makes it longer than necessary for answering the specific question about probabilities.",3.0,"The LLM output is faithful to cBioPortal's capabilities and limitations. It correctly states that cBioPortal doesn't directly calculate conditional probabilities, provides legitimate navigation paths using the tool's API, and doesn't hallucinate features or data. All the URLs and approaches are based on actual cBioPortal functionality as evidenced by the tool responses.",104695,1593,29.957977551035583,,
